Cefpirome + SulbactamThird Party Manufacturing in India

Cefpirome + Sulbactam works by pairing a fourth-generation zwitterionic cephalosporin with an irreversible beta-lactamase inhibitor. Cefpirome penetrates bacterial outer membranes rapidly to bind to penicillin-binding proteins, inhibiting cell wall peptidoglycan cross-linking and causing cell lysis. Sulbactam binds to and inactivates beta-lactamase enzymes produced by resistant bacteria, protecting cefpirome from degradation and restoring its core antibacterial activity. This combination expands the spectrum of activity against many beta-lactamase-producing Gram-negative and Gram-positive pathogens. It is highly effective and well-tolerated.

Therapeutic Uses

• Refractory Nosocomial Infections: Treats severe, resistant hospital-acquired infections that do not respond to first-line regimens.
• Severe Intra-Abdominal Sepsis: Provides broad-spectrum coverage for managing complex intra-abdominal infections and peritonitis.
• Complicated Skin and Soft Tissue Infections: Addresses deep, necrotizing tissue infections involving beta-lactamase-producing organisms.

Why Manufacturers Choose Cefpirome + Sulbactam

This fourth-generation combination helps counter broad-spectrum resistance in hospital environments, maintaining stable demand in critical care sectors. Contracting for Cefpirome + Sulbactam third party manufacturing in India helps brands build a robust critical care portfolio. Formulated with premium CAS number 84957-29-9 combination bases in WHO-GMP certified partner installations, this dry injection meets strict quality and safety criteria.